No profile data available.
enGene Holdings Inc. (ENGN) is a healthcare company in the additional cancer treatment drugs industry, based in Montreal, Canada, with about 81 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$117.30 million. In Q3 2026 (the quarter ended July 31, 2026) revenue was $0. Its market capitalization was $115.94 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended October 31, 2025; market data as of October 9, 2026.
, operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2.
enGene reported $0 in revenue for fiscal year 2025. In Q3 2026 revenue was $0.
$115.94 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include TuHURA Biosciences, Inc. (HURA), Inovio Pharmaceuticals, Inc. (INO), Foghorn Therapeutics Inc. (FHTX), Genelux Corporation (GNLX).